Navigation Links
Vermillion Reports Results for Third Quarter 2011
Date:11/9/2011

ares authorized, none issued and

--outstanding at September 30, 2011 and December 31, 2010Common stock, $0.001 par value, 150,000,000 shares authorized at September 30, 2011and December 31, 2010; 14,848,301 and 10,657,564 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively

1511Additional paid-in capital

326,476303,270Accumulated deficit

(313,164)(298,509)Accumulated other comprehensive loss

(152)(156)Total stockholders’ equity

13,1754,616Total liabilities and stockholders’ equity

$
28,046$
24,035Vermillion, Inc.Consolidated Statements of Operations(Amounts in Thousands, Except Share and Per Share Amounts)(Unaudited)Three Months Ended September 30, Nine Months Ended September 30, 2011201020112010Revenue:Product revenue

$
206$
4$
714$
59License revenue

114299341671Total revenue

3204131,055830Cost of revenue:Product

261310525Total cost of revenue

261310525Gross profit

294400950805Operating expenses:Research and development(1)

1,3701,1114,2192,797Sales and marketing(2)

1,4991,0254,3201,751General and administrative(3)

1,9521,8646,9826,604Total operating expenses

4,8214,00015,52111,152Loss from operations

(4,527)(3,600)(14,571)(10,347)Interest income

18125525Interest expense

(100)(117)(330)(375)Change in fair value and gain from exercise of warrants, net

329803744,427Debt conversion costs

---(141)Reorganization items

(42)(44)(74)(1,641)Reorganization items - related party incentive plan

---(6,932)Other income (expense), net

(32)33(109)(36)Loss before income taxes

(4,651)(2,736)(14,655)(15,020)Income tax expense

----Net loss

$
(4,651)$
(2,736)$
(14,655)$
(15,020)Net loss per share - basic and diluted

$
(0.31)$
(0.26)$
(1.04)$
(1.45)Weighted average common shares
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
2. Vermillion Engages Liolios Group to Lead Investor Relations Program
3. Vermillion Enhances Management Team With A Key Addition
4. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
5. Vermillion Reports Financial Results for the First Quarter 2011
6. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
7. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
8. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
9. Vermillion Announces $21.8 Million Public Offering
10. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
11. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... , April 27, 2010 Shire plc (LSE: ... it has received a Paragraph IV Notice Letter from Anchen,Pharmaceuticals, ... Application ("ANDA") for a generic version of Shire,s 1 mg, ... tablets, INTUNIV(TM).,Shire had previously reported in March 2010 ...
... April 27 For a second consecutive year, following the ... Auto Thefts) is cautioning Michigan drivers, and now auto dealers ... theft-related crimes.   , , ... increased vehicle security features, and the continuing success of Michigan ...
Cached Medicine Technology:Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 2Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 3H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 2H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 3
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... at the University of Iowa Roy J. and Lucille A. ... (PET) technology can help // doctors gauge the response of ... and co-author Bruce Cheson, M.D., of the Lombardi Comprehensive Cancer ... usage of PET n gauging the response of the tumor ...
... loan of $ 260 M to Kenya by the World ... be in rough weather as it has been delayed due ... ,The corruption charges are against the Kenyan government, the ... ,According to the Kenyan Ministry of Health in February 2005 ...
... Biocon, an Indian biotechnology company will raise its investments ... destination for clinical development of drugs. Biocon is reported ... with life sciences organizations in Scotland. There are more ... than 26,500 people. Scotland will serve to fill the ...
... Won Jang of the Department of Internal Medicine at the ... that administering an antiviral drug would help prevent hepatitis ... treatment of cancer. ,In hepatocellular carcinoma (HCC), patients ... a result of chemotherapy. Hepatocellular carcinoma or liver cancer is ...
... has found prominence again, for the wrong reasons. Blaming the ... // held the post of Chief Scientific Officer at ... the risks of MMR triple vaccine adequately, despite a lurking fear ... if this doubt is proved, it could turn out to be ...
... implantation of stem cells into the pancreas of type 2 ... endogenous insulin. // In addition, it has been associated with ... decrease in blood sugar levels. ,If approved, this ... diabetics from receiving insulin or drugs to stimulate the production ...
Cached Medicine News:Health News:Hepatitis B Relapse In Cancer Chemotherapy Can Be Avoided By Antiviral Drug 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: